Labiotech.eu

News and Trends 5 Apr 2023

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

In Depth 5 Apr 2023

Antimicrobial peptides: a promising class to tackle antimicrobial resistance

The discovery of penicillin in 1928 by Alexander Fleming was a momentous moment in the world of healthcare, eventually leading to the development of antibiotic drugs that allowed physicians to treat illnesses and infections that were once severe and life-threatening. But our reliance on antibiotics has now led to an emerging global health problem in […]

April 5, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 5 Apr 2023

Cure Ventures launches with $350M to support life sciences companies

Cure Ventures, a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, has closed its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The fund is supported by a syndicate of U.S. and internationally-based investors that includes state and city public pension […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Mosaic Therapeutics closes $28M series A funding

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […]

April 5, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 4 Apr 2023

6 biotechs that have stepped into the protein degradation space

Protein degradation platforms have revolutionized drug discovery aimed at undruggable targets. Biopharmaceutical companies around the world have engaged in the protein degradation field, with the hope of leveraging the capabilities of these coumpounds to successfully design drugs to treat diseases like cancer and neurodegenerative disorders. The discovery of the ubiquitin and proteolysis – protein degradation […]

April 4, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Alzamend pushing ahead with Alzheimer’s vaccine trial

Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose of the trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of Alzamend Neuro’s ALZN002 compared with that of placebo in […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

iNtRON looks to control colorectal cancer through microbiome

iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) for cancer control. Bacteriophages have been used for R&D on bacterial infectious diseases, but recently […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

New research may lead to gene therapies for kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal genetic disease—about a half million people in the U.S. alone suffer from the condition. There is currently no cure, but new research could open the door to new gene therapies for treating most cases of this kidney disease. For several decades, researchers have […]

April 4, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Discovery could lead to cancer drugs with fewer side effects

Many anticancer drugs have serious side-effects in clinical practice. Kinesin inhibitors block kinesin motor proteins required for cancer cell division, and are promising anticancer drug candidates with minimal side-effects. However, their association with kinesin proteins remains unclear. Researchers from Japan have addressed this by solving the crystal structure of the complex formed by the kinesin […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

BIO-Europe Spring 2023: The Highlights

BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel, Switzerland, was in full swing […]

April 3, 2023 - 28 minutesmins - By External Contributor

digital medicine artificial intelligence AI

News and Trends 31 Mar 2023

Sofinnova Partners dives into digital medicine, funds new companies

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine. The strategy, which has already seen Sofinnova Partners investing in biotech companies, will be headed by partners Edward Kliphuis and Simon Turner. Sofinnova Digital Medicine will back entrepreneurs innovating at […]

March 31, 2023 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Antimicrobial peptides: a promising class to tackle antimicrobial resistance

Cure Ventures launches with $350M to support life sciences companies

Mosaic Therapeutics closes $28M series A funding

6 biotechs that have stepped into the protein degradation space

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Alzamend pushing ahead with Alzheimer’s vaccine trial

iNtRON looks to control colorectal cancer through microbiome

New research may lead to gene therapies for kidney disease

Discovery could lead to cancer drugs with fewer side effects

BIO-Europe Spring 2023: The Highlights

Sofinnova Partners dives into digital medicine, funds new companies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!